Integral Diagnostics (ASX:IDX) Research & Development: A$0.0 Mil (TTM As of Dec. 2025)


ASX:IDX Integral Diagnostics Ltd ASX:IDX
73 GF Score
Price A$2.01
GF Value A$2.78
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Integral Diagnostics Research & Development?

Integral Diagnostics ASX:IDX +1.77% 73 Research & Development is A$0.0 Mil as of Dec. 2025. GuruFocus rates ASX:IDX with a GF Score™ of 73/100 and a GF Value™ of A$2.78 (Modestly Undervalued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Integral Diagnostics's Research & Development for the six months ended in Dec. 2025 was A$0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.0 Mil.

Integral Diagnostics  (ASX:IDX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Integral Diagnostics Research & Development Related Terms

Integral Diagnostics Research & Development Historical Data

* Premium members only.

The historical data trend for Integral Diagnostics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integral Diagnostics Research & Development Chart

Integral Diagnostics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Integral Diagnostics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:IDX
73GF Score
Integral Diagnostics Ltd ASX:IDX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integral Diagnostics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.0 Mil mean?
Integral Diagnostics (ASX:IDX) has a Research & Development of A$0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Integral Diagnostics and its competitors.
Is Integral Diagnostics' Research & Development too high?
Integral Diagnostics' current Research & Development is A$0.0 Mil. Overall, Integral Diagnostics has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' Research & Development compare to TMO and DHR?
Integral Diagnostics' Research & Development of A$0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Integral Diagnostics and its competitors. Integral Diagnostics's current Research & Development is A$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.78, compared to a current price of A$2.01 — trading 27.7% below its estimated fair value. The current Research & Development is A$0.0 Mil. Integral Diagnostics' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current Research & Development is A$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?

Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued. The current stock price of A$2.01 is trading 27.7% below its estimated GF Value™ of A$2.78. GuruFocus considers Integral Diagnostics to be Modestly Undervalued.

Key valuation signals for ASX:IDX:

  • Research & Development: A$0.0 Mil
  • GF Value™: A$2.78 vs. price of A$2.01 (27.7% below fair value)
  • GF Score™: 73/100 with 9 warning signs

No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integral Diagnostics Business Description

Address 288 Victoria Parade, Level 2, Melbourne, VIC, AUS, 3002
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
73GF Score

Get the complete analysis for ASX:IDX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.01
Price
A$2.78
GF Value